Literature DB >> 23791388

Cutaneous manifestations of Nocardia brasiliensis infection in Taiwan during 2002-2012-clinical studies and molecular typing of pathogen by gyrB and 16S gene sequencing.

Kuo-Wei Chen1, Chun-Wei Lu, Ting-Chi Huang, Chin-Fang Lu, Yea-Ling Liau, Jeng-Fong Lin, Shu-Ying Li.   

Abstract

To observe the clinicopathologic and resistance profiles of the Nocardia brasiliensis causing cutaneous nocardiosis in Taiwan, 12 N. brasiliensis isolates were prospectively collected from patients with cutaneous nocardiosis in a hospital during 2002-2012. Clinicopathologic data were obtained, and isolates were identified by biochemical methods and 16S rRNA sequencing. Susceptibilities to 14 antimicrobial compounds were tested. Isolates were further genotyped by sequencing of 16S rRNA, secA1, hsp65, and gyrB genes. The nodulopustular pyoderma associated with sporotrichoid spreading was the most common skin presentations caused by N. brasiliensis. All of the isolates were susceptible to amikacin, gentamicin, tobramycin, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole and resistant to kanamycin, erythromycin, and oxacillin, while susceptibilities to imipenem, vancomycin, penicillin-G, tetracycline, clindamycin, and ciprofloxacin varied among the 12 isolates. GyrB genotyping delineated the 12 isolates into 2 major groups, which was coincident with different single nucleotide substitutions at position 160 (G versus T) of 16S rRNA, different levels of imipenem minimum inhibition concentration (4-32 versus 0.25-0.75 mg/L), and prevalence of lymphadenitis (66.7 versus 16.7%). We have noted that tiny pustular lesions can be the first sign of cutaneous nocardiosis, which we believe has not been previously emphasized. No resistance to trimethoprim and sulfamethoxazole was found; therefore, sulphonamide drugs remain effective for treatment of cutaneous nocardiosis in Taiwan.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  16S rRNA; Cutaneous nocardiosis; Drug resistance; Molecular typing; Nocardia brasiliensis; gyrB; hsp65; secA1

Mesh:

Substances:

Year:  2013        PMID: 23791388     DOI: 10.1016/j.diagmicrobio.2013.05.008

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  gyrB analysis as a tool for identifying Nocardia species and exploring their phylogeny.

Authors:  Gema Carrasco; Sylvia Valdezate; Noelia Garrido; María J Medina-Pascual; Pilar Villalón; Juan A Sáez-Nieto
Journal:  J Clin Microbiol       Date:  2014-12-24       Impact factor: 5.948

2.  Cutaneous Nocardiosis Simulating Cutaneous Lymphatic Sporotrichosis.

Authors:  Pedro Secchin; Beatriz Moritz Trope; Larissa Araujo Fernandes; Glória Barreiros; Marcia Ramos-E-Silva
Journal:  Case Rep Dermatol       Date:  2017-08-17

3.  An unusual successful treatment with non-sulfonamides: primary cutaneous nocardiosis caused by Nocardia brasiliensis.

Authors:  Nian Chen; Qin Qin; Ke-Dai Sun; Dan Luo; Qiong-Hui Cheng
Journal:  Ther Clin Risk Manag       Date:  2018-09-10       Impact factor: 2.423

Review 4.  Primary Cutaneous Nocardiosis in a Patient With Nephrotic Syndrome: A Case Report and Review of the Literature.

Authors:  Bing Chen; Jin Tang; Zeyuan Lu; Niansong Wang; Xuping Gao; Feng Wang
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

5.  Sporotrichoid Skin Infection Caused by Nocardia brasiliensis in a Kidney Transplant Patient.

Authors:  Folusakin Ayoade; Pradeep Mada; Andrew Stevenson Joel Chandranesan; Mohammed Alam
Journal:  Diseases       Date:  2018-07-25

6.  Lymphocutaneous nocardiosis caused by Nocardia brasiliensis in an immunocompetent patient: a case report.

Authors:  Siying Li; Xiangfei Xu; Min Wu; Jing Zhu; Panpan Cen; Jiexia Ding; Shenghai Wu; Jie Jin
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

Review 7.  Isolated Nocardiosis, an Unrecognized Primary Immunodeficiency?

Authors:  Rubén Martínez-Barricarte
Journal:  Front Immunol       Date:  2020-10-20       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.